7 assets in Vaginal Squamous Cell Carcinoma

Therapeutic assets addressing Vaginal Squamous Cell Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Atezolizumab Vaginal Squamous Cell Carcinoma	M.D. Anderson Cancer Center	P2	CCC (53)
Ipilimumab Vaginal Squamous Cell Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Vaginal Squamous Cell Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Cyclophosphamide Vaginal Squamous Cell Carcinoma	SCG Cell Therapy Pte. Ltd.	P1/2	CCC (48)
Fludarabine Vaginal Squamous Cell Carcinoma	SCG Cell Therapy Pte. Ltd.	P1/2	CCC (48)
scg142 Vaginal Squamous Cell Carcinoma	SCG Cell Therapy Pte. Ltd.	P1/2	CCC (48)
Evolve104 Vaginal Squamous Cell Carcinoma	EvolveImmune United, Inc	P1	NR ()